Cargando…
A randomised controlled trial to evaluate a medication monitoring system for TB treatment
BACKGROUND : Adherence to TB treatment and therefore treatment success could be improved using digital adherence technology. OBJECTIVE : To evaluate the effectiveness of a medication event reminder monitor system (MERM) on treatment success and treatment adherence in patients with drug-susceptible p...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Union Against Tuberculosis and Lung Disease
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734191/ https://www.ncbi.nlm.nih.gov/pubmed/34969428 http://dx.doi.org/10.5588/ijtld.21.0373 |
_version_ | 1784627964817702912 |
---|---|
author | Acosta, J. Flores, P. Alarcón, M. Grande-Ortiz, M. Moreno-Exebio, L. Puyen, Z. M. |
author_facet | Acosta, J. Flores, P. Alarcón, M. Grande-Ortiz, M. Moreno-Exebio, L. Puyen, Z. M. |
author_sort | Acosta, J. |
collection | PubMed |
description | BACKGROUND : Adherence to TB treatment and therefore treatment success could be improved using digital adherence technology. OBJECTIVE : To evaluate the effectiveness of a medication event reminder monitor system (MERM) on treatment success and treatment adherence in patients with drug-susceptible pulmonary TB in Perú. METHODS : This was an experimental, randomised, open-label, controlled study conducted among patients in the second phase of TB treatment. The intervention group received their medications through MERM with the support of a treatment monitor, whereas the control group used the usual strategy. Participants were followed until they completed the 54 doses of the second phase of treatment. RESULTS : The study included 53 patients in each group; four in the intervention group withdrew from the study. Treatment success was significantly more frequent in the MERM group (RR 1.15, 95% CI 1.02–1.30; P = 0.0322). There was no significant difference in the adherence outcomes; however, the percentage of patients who missed at least one dose and patients with more than 10% of total doses missed were lower in the intervention group. CONCLUSION : The use of MERM in the second phase of treatment showed a significant improvement in the treatment success rate in patients with drug-susceptible pulmonary TB. |
format | Online Article Text |
id | pubmed-8734191 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | International Union Against Tuberculosis and Lung Disease |
record_format | MEDLINE/PubMed |
spelling | pubmed-87341912022-01-07 A randomised controlled trial to evaluate a medication monitoring system for TB treatment Acosta, J. Flores, P. Alarcón, M. Grande-Ortiz, M. Moreno-Exebio, L. Puyen, Z. M. Int J Tuberc Lung Dis Original Articles BACKGROUND : Adherence to TB treatment and therefore treatment success could be improved using digital adherence technology. OBJECTIVE : To evaluate the effectiveness of a medication event reminder monitor system (MERM) on treatment success and treatment adherence in patients with drug-susceptible pulmonary TB in Perú. METHODS : This was an experimental, randomised, open-label, controlled study conducted among patients in the second phase of TB treatment. The intervention group received their medications through MERM with the support of a treatment monitor, whereas the control group used the usual strategy. Participants were followed until they completed the 54 doses of the second phase of treatment. RESULTS : The study included 53 patients in each group; four in the intervention group withdrew from the study. Treatment success was significantly more frequent in the MERM group (RR 1.15, 95% CI 1.02–1.30; P = 0.0322). There was no significant difference in the adherence outcomes; however, the percentage of patients who missed at least one dose and patients with more than 10% of total doses missed were lower in the intervention group. CONCLUSION : The use of MERM in the second phase of treatment showed a significant improvement in the treatment success rate in patients with drug-susceptible pulmonary TB. International Union Against Tuberculosis and Lung Disease 2022-01-01 2022-01-01 /pmc/articles/PMC8734191/ /pubmed/34969428 http://dx.doi.org/10.5588/ijtld.21.0373 Text en © 2022 The Union https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Original Articles Acosta, J. Flores, P. Alarcón, M. Grande-Ortiz, M. Moreno-Exebio, L. Puyen, Z. M. A randomised controlled trial to evaluate a medication monitoring system for TB treatment |
title | A randomised controlled trial to evaluate a medication monitoring system for TB treatment |
title_full | A randomised controlled trial to evaluate a medication monitoring system for TB treatment |
title_fullStr | A randomised controlled trial to evaluate a medication monitoring system for TB treatment |
title_full_unstemmed | A randomised controlled trial to evaluate a medication monitoring system for TB treatment |
title_short | A randomised controlled trial to evaluate a medication monitoring system for TB treatment |
title_sort | randomised controlled trial to evaluate a medication monitoring system for tb treatment |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734191/ https://www.ncbi.nlm.nih.gov/pubmed/34969428 http://dx.doi.org/10.5588/ijtld.21.0373 |
work_keys_str_mv | AT acostaj arandomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment AT floresp arandomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment AT alarconm arandomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment AT grandeortizm arandomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment AT morenoexebiol arandomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment AT puyenzm arandomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment AT acostaj randomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment AT floresp randomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment AT alarconm randomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment AT grandeortizm randomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment AT morenoexebiol randomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment AT puyenzm randomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment |